Heart Failure

Articles on this topic

ESC 2022: Initiating Gliflozin in HFpEF During Hospitalization Can Benefit the Patient. This is Also Evidenced by Experience from the USA

Based on evidence from clinical studies, gliflozins are currently being introduced into…

7. 10. 2022 Source: Heart Failure

Emotional joyful patient telling his doctor good news

Benefit of Adding Empagliflozin to Standard Therapy in Heart Failure with Reduced Ejection Fraction

The use of empagliflozin led to a reduction in the risk of hospitalization for heart failure…

5. 8. 2022 Source: Heart Failure

Increase in Hematocrit During Empagliflozin Treatment in a Diabetic Patient with Severe Anemia −⁠ A Case Study

In a case study involving a 78-year-old diabetic patient, where only the administration of…

26. 7. 2022 Source: Heart Failure

Influence of ARNI on the Efficacy and Safety of Empagliflozin in the Treatment of Heart Failure with Reduced Ejection Fraction

Pharmacological inhibition of neprilysin and the AT1 receptor for angiotensin II (ARNI)…

13. 7. 2022 Source: Heart Failure

Summary of New American Recommendations for Heart Failure Management

This year, the American Heart Association (AHA), the American College of Cardiology (ACC), and…

28. 6. 2022 Source: Heart Failure

Does empagliflozin improve the overall health of patients with heart failure with reduced LVEF?

A recently published secondary analysis of the EMPEROR-Reduced study is based mainly on the…

21. 6. 2022 Source: Heart Failure

Empagliflozin Secures Reimbursement for Heart Failure Treatment

Starting May 1st, health insurance companies will cover Jardiance^® (empagliflozin) for…

3. 5. 2022 Source: Heart Failure

srdeční selhání se zachovalou ejekční frakcí

Efficacy and Safety of Empagliflozin in Patients with Heart Failure with Preserved Ejection Fraction

Previous studies have shown that the antidiabetic drug empagliflozin reduces the risk of…

27. 4. 2022 Source: Heart Failure

Gliflozins Successfully Treat Type 2 Diabetes Mellitus and Heart Failure

The number of patients with type 2 diabetes mellitus (DM2) and heart failure is increasing…

25. 4. 2022 Source: Heart Failure

EMA Approved Empagliflozin for the Treatment of Heart Failure Regardless of Left Ventricular Ejection Fraction

Prague, March 8, 2022 –⁠ Hundreds of thousands of patients in the Czech Republic can soon look…

8. 3. 2022 Source: Heart Failure

Does gliflozin treatment for heart failure have greater benefits in diabetics?

Inhibitors of glucose reabsorption in the proximal tubule are represented on the domestic…

3. 3. 2022 Source: Heart Failure

Proposal of a New Treatment Sequence Algorithm for Heart Failure with Reduced Ejection Fraction

John McMurray and Milton Packer published a proposal for a new treatment sequence algorithm…

21. 2. 2022 Source: Heart Failure

Reverse Remodeling of LV in Patients with Diabetes/Prediabetes and Heart Failure with Reduced Ejection Fraction Treated with Empagliflozin

Authors of the British study SUGAR-DM-HF published in February 2021 examined whether…

14. 1. 2022 Source: Heart Failure

Empagliflozin in the Treatment of Patients with Chronic Heart Failure

Unlike other antidiabetics, sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk…

7. 12. 2021 Source: Heart Failure

Reduction of Risk of Hospitalizations for Heart Failure in Type 2 Diabetics

The EMPA-REG OUTCOME study already in 2015 highlighted one of the benefits of the…

2. 12. 2021 Source: Heart Failure

1 2 3

E-courses on this topic

Authors: MUDr. Sylvie Štrégl Hrušková, prof. MUDr. Michal Vrablík, Ph.D., prof. MUDr. Vojtěch Melenovský, CSc., MUDr. Marie Lazárová

Course detail

Authors: MUDr. Kristýna Kyšperská, MUDr. Jan Beneš

Course detail

Conferences news

Sjezd ČKS 2024: Výzvy v péči o pacienty se srdečním selháním a možnosti jejich řešení

3. 5. 2024 - 6. 5. 2024

2 records

Go to records